The FDA has a program called Fast Track. It is a program that puts new drug reviews on an expedited track for review. Multiple Sclerosis Campath therapy is now on that track. For the manufacturer and patients with MS, Campath being put on this list is welcome news.  Under this designation, Multiple Sclerosis Campath treatment marketing applications can be reviewed before the submission of the New Drug Application is complete. So if the drug is finally approved, MS Campath therapy will be available much quicker for actual use than if the drug remained under the normal review process.

MS Campath therapy could be transformative.

Campath is primarily targeting the early diagnosed relapsing-remitting multiple sclerosis patient.  It is in trial along with Rebif for patients that have not received any prior therapies for their RRMS since being diagnosed.  It requires only minimal annual dosing compared with many other drugs.  …